Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Waters Corporation (NYSE: WAT), a global life sciences and diagnostics leader, today announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp's nationwide laboratory network beginning in late 2026.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
